Fewer unadjusted COPD exacerbations were recorded in GLP-1 receptor users compared to significantly higher adjusted exacerbation rates with dipeptidyl peptidase 4 (DPP-4) inhibitor users and sulfonylurea users. The gene discussed is GLP1R; the disease is chronic obstructive pulmonary disease.